Advertisement

Topics

Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from

13:01 EDT 14 Mar 2018 | BioPortfolio Report Blog

Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 Pipeline Review, H1 2018


Summary


Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.


The latest report Macrophage Migration Inhibitory Factor Pipeline Review, H1 2018, outlays comprehensive information on the Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 Macrophage migration inhibitory factor MIF also known as glycosylationinhibiting factor GIF is a protein that is encoded by the MIF gene. Macrophage migration inhibitory factor MIF is a pleiotropic cytokine produced by the pituitary gland and multiple cell types, including macrophages, dendritic cells DC and Tcells.


Upon releases MIF modulates the expression of several inflammatory molecules, such as TNF, nitric oxide and cyclooxygenase 2 COX2. MIF is an important regulator of innate immunity. Antigens stimulate white blood cells to release MIF into the blood stream. The circulating MIF binds to CD74 on other immune cells and trigger an acute immune response. MIF plays a role in the regulation of macrophage function in host defense through the suppression of antiinflammatory effects of glucocorticoid.


The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Dermatology and Respiratory which include indications Glomerulonephritis, Inflammatory Bowel Disease, Pulmonary Arterial Hypertension, Rheumatoid Arthritis, Type 1 Diabetes Juvenile Diabetes, Alcohol Addiction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Asthma, Atopic Dermatitis, Crohn's Disease Regional Enteritis, Drug Addiction, Globoid Cell Leukodystrophy Krabbe Disease, Multiple Sclerosis, Myocardial Infarction, Obesity, Opium Withdrawal Syndrome, Primary Progressive Multiple Sclerosis PPMS, Psoriasis, Recurrent Glioblastoma Multiforme GBM, Secondary Progressive Multiple Sclerosis SPMS, Solid Tumor, Systemic Lupus Erythematosus, Traumatic Brain Injury, Type 2 Diabetes and Ulcerative Colitis.


Furthermore, this report also reviews key players involved in Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 targeted therapeutics development with respective active and dormant or discontinued projects.


Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12

The report reviews Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 targeted therapeutics and enlists all their major and minor projects

The report assesses Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from

NEXT ARTICLE

More From BioPortfolio on "Macrophage Migration Inhibitory Factor Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12 Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Cytokine
Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...